In a phase 3 RCT of adults with cUTI or acute pyelonephritis (431 of 614 in primary analysis), composite success was 82% with cefepime-nacubactam (non-inferior and superior), 72% with aztreonam-nacubactam (non-inferior) and 61% with imipenem-cilastatin.
RCTn = 614
Takahashi et al. Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial